I agree with you, very exciting prospects for the company.
Here is a quote from the interview:
"We collaborate with HemoGenix down in Colorado Springs, which is important in terms some of our cell-based assay development. Celartia is another company that we collaborate with and there are others as well. We have limited resources ourselves, so collaborations are really very important for acceleration of our growth. Our prior collaboration with Neuromics has evolved to the point where we’re planning to combine the companies. A key component of this synergy comes from Pete Shuster’s expertise in sales and marketing. We’re, again, mainly a technology/manufacturing company and through his expertise in sales and marketing we anticipate ability of penetrate some of these key markets in clinical stem cell products that I described earlier."
HemoGenix, Dr. Ian Smith, recently raised $500,000 in a private offering, prior to the announcement regarding Neuromics and VODG. Those who looked at the information provided to potential investors, had to have walked away with the impression expressed in the comment above regarding the collaborative work, which is now public. Someone with inferential analytical skills would no doubt link these three companies together in their collaborative issues - each bringing unique skills and opportunities to investors. Two are in the process of becoming one with exciting synergies as Dr. Musick expressed in his interview. It would appear to me from what he has stated in his interview that these collaborative efforts may well offer shareholders in VODG even more exciting opportunities as this business grows into a much more competitive company as a result.
Seems to me shareholders should be quite excited and regarding the question about why anyone would be selling stock at these levels - don't forget the amount of volume from the pump and dumpsters - over one years worth over a brief period, many buyers had to be sheep.
AI
